February 14, 2023
8,678
119
77
2.26%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
0:44Now PlayingScientists are reporting a breakthrough discovery: A $3-per-pill epilepsy drug may be used to “switch off” autism symptoms in mice, according to a new peer-reviewed study published Tuesday in Molecular Psychiatry journal.
Autism spectrum disorder is a complex developmental condition that impacts how an estimated 5.4 million (2.2%) adults — and one in 44 children — in the United States perceives and socializes with others. It is often accompanied by abnormalities such as epilepsy or hyperactivity, according to Centers for Disease Control and Prevention data.
A team of experts at Germany’s Hector Institute for Translational Brain Research found that the medication lamotrigine — an anti-seizure drug first approved for use in the US in 1994 — was able to curb behavioral and social problems linked to the disorder.
Now, their findings are being hyped as the closest thing yet to a potential cure for humans.
“Apparently, drug treatment in adulthood can alleviate brain cell dysfunction and thus counteract the behavioral abnormalities typical of autism,” lead researcher and cellular biologist Moritz Mall said in a statement. “[This occurs] even after the absence of MYT1L has already impaired brain development during the developmental phase of the organism.”
Lamotrigine, which is sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in those who suffer from bipolar disorder.
The drug, which typically sells for just under $3 per pill, works by reversing changes to brain cells caused by a genetic mutation.
Read more at
#autism #epilepsy #science #medicine
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Subscribe to New York Post Sports
Catch the latest news here
Follow The New York Post on:
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.